Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR2 Fusion”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Not applicableLooking for participantsNCT07151118
What this trial is testing

CtDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
CHA University 100
Testing effectiveness (Phase 2)WithdrawnNCT05222165
What this trial is testing

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Who this might be right for
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Helsinn Healthcare SA
Large-scale testing (Phase 3)Not Yet RecruitingNCT07328919
What this trial is testing

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)Advanced Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc. 138
Not applicableStudy completedNCT02762721
What this trial is testing

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

Who this might be right for
Intrahepatic CholangiocarcinomaMixed Hepatocellular CholangiocarcinomaCholangiocarcinoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 131
Testing effectiveness (Phase 2)Study completedNCT03230318
What this trial is testing

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Basilea Pharmaceutica 148
Not applicableLooking for participantsNCT06793709
What this trial is testing

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Who this might be right for
Biliary Tract Cancer
Eisai Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT07786766
What this trial is testing

Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma

Who this might be right for
Biliary Tract Cancer (BTC)
Haitao Zhao, MD 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Not applicableStudy completedNCT02450123
What this trial is testing

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumors
Samsung Medical Center 1
Testing effectiveness (Phase 2)Looking for participantsNCT07359820
What this trial is testing

Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Who this might be right for
FGFR2 Gene Fusion/RearrangementOther Solid Tumors, Adult
Elevar Therapeutics 30
Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208